Issue 31

First PSYCH Investor Summit Programming Announced: In Conversation with Christian Angermayer & Rick Doblin

How can successful for-profit psychedelics organisations and investors support the change-making work of non-profits? What is the role of each in an increasingly competitive business ecosystem, where are the friction points and what does the ideal relationship look like?

PSYCH is pleased to announce the first, highly anticipated discussion of the PSYCH Investor Summit: Research and Development, a conversation between atai Life Sciences’ founder, Christian Angermayer and Multidisciplinary Association for Psychedelic Studies (MAPS) founder, Rick Doblin.

Join us on 7 July for this can’t-miss event. In a US$100 billion industry set to disrupt modern healthcare, hear important insights on the critical path forward from these leaders on the frontlines.

DIRECTOR OF THE NATIONAL INSTITUTES OF HEALTH PRAISES PSYCHEDELIC RESEARCH

Francis Collins, the highest-ranking health officer in the U.S., praised the potential of psychedelic research during a Senate budget hearing last week.

READ MORE

CALIFORNIA SENATE APPROVES BILL TO LEGALISE POSSESSION OF PSYCHEDELICS

If passed into law, the bill will remove criminal penalties for possessing or sharing psychedelics, including psilocybin, LSD and MDMA.

READ MORE

BUSINESS & INVESTMENT


Field Trip receives approval for Toronto Stock Exchange listing.


Wesana hires renowned psychedelics expert to assist with brain trauma research.


NeonMind announces board of experts to guide rollout of psychedelic therapy clinics.


Myconic Capital changes name to Ketamine One and expands leadership team.


MYND Life Sciences announces new programme to better diagnose and treat depression.


PharmaTher partners with biotech company to develop microneedle patches for psychedelics.


Novamind announces US$1.9 million Q3 revenue and other operating highlights.


Cresco Pharma target Halucenex Life Sciences progresses psychedelic US market entry strategy.


Psyence finalising agreements with Jamaican partners to develop natural psilocybin-based formulations.


PharmaTher and MediSynergics developing ketamine formulation to treat pain disorders.


Cybin sponsors study to measure ketamine’s effects on the brain during psychedelic treatments.


Small Pharma announces expansion of clinical trial for DMT-based depression treatment.


Psyence announces updates on therapeutic psychedelics development.


Algernon Pharmaceuticals highlights Hungarian university’s study showing potential for DMT as stroke treatment.


Filament enters sales agreement worth up to C$10 million.


The Good Shroom Co. signs contract with Canadian retail distribution giant Ecotrend.


Braxia Scientific appoints mental health and concussion specialist to Board of Directors.


Algernon Pharmaceuticals shares animal study confirming effectiveness of DMT in treating strokes.


Delic completes acquisition of psilocybin research lab.

RESEARCH & SCIENCE


National Institutes of Health Director praises potential of psychedelics during Senate budget hearing.


Growing number of researchers turning to psychedelics to relieve symptoms of autism.


How ketamine can help patients manage severe depression.


Australian psychologists signing up for psychedelic therapy training.


A clinical counsellor describes his legal trip on psilocybin mushrooms.


Mental health researchers and practitioners discuss how love relates to psychedelic-assisted therapy.


Scientists show how LSD blows open the doors of perception.


Ketamine could be a game-changer in treating eating disorders.


Non-hallucinogenic psychedelic analogs could revolutionise neuropsychiatry.


Study shows analogue of psychedelic ibogaine reverses effects of stress in mice.

REGULATION & LEGISLATION


Physician suing DEA over psilocybin access with strong backing from scientific community.


Does the DEA have to allow psilocybin access for terminally ill patients?


Texas psychedelics research bill headed for governor’s approval.


Case-by-case policy leaves Australians waiting for access to psychedelics-assisted therapy.